MetaCap

enGene Therapeutics Inc. (ENGN)

NASDAQ: ENGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.74-0.02 (-1.14%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ENGN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$116.61M
EPS (TTM)
-$2.07
52-week range
1.40 – 12.25
Day range
1.69 – 1.80
Volume / Avg
556.72K / 1.12M
Beta
—

52-week range

$1.40$12.25

ENGN stock today

Shares of enGene Therapeutics (ENGN) finished lower on Nov 20 at $1.74, a drop of 1.14% or $0.02 per share, versus the S&P 500's 3.70% decline. Trading was light, with 556.72K shares changing hands, about 50% of the average daily volume. At this level, ENGN sits near the bottom of its 52-week range of $1.40 to $12.25: 85.8% below the high, set on Jan 23, 2026 and 24.3% above the low.

ENGN is down 80.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 75.0%. enGene Therapeutics has posted a net loss over the last twelve months (EPS of -$2.07), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About enGene Therapeutics

Company profile

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Ronald H. W. Cooper
Headquarters
Montreal, QC
Employees
81
Website
engene.com

Financial highlights

Full financials

enGene Therapeutics reported a net loss of $117.3 million, compared with a loss of $55.1 million a year earlier. Diluted earnings per share came in at $2.29, up from $1.46.

enGene Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue————
Growth————
Net income$-117.30M$-55.14M$-99.92M$-24.46M
EPS (diluted)$2.29$1.46$151.22$44.30

Analyst forecast

Forecast

Consensus (9 analysts)

buy

Avg. price target

$4.29+146.55%

  • Strong buy 2
  • Buy 4
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $6.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Q3 2026)
Sep 8, 2026
EPS actual vs est.
$-0.47 vs —

ENGN news

All ENGN news

enGene Therapeutics peers

Health Care sector
ENGN peer companies
CompanyPrice% ChgMarket capCompare
IVVDInvivyd Inc.0.4127-7.45%$122.01Mvs ENGN
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs ENGN
HUMAHumacyte Inc.0.4454-17.90%$123.73Mvs ENGN
CMPXCompass Therapeutics Inc.0.6882+1.43%$123.94Mvs ENGN
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs ENGN
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs ENGN
MOLNMolecular Partners AG ADR2.53-5.25%$96.80Mvs ENGN
IPHAInnate Pharma S.A. ADS0.8634-8.14%$96.44Mvs ENGN

Indexes, lists and sector

enGene Therapeutics stock FAQ

What is enGene Therapeutics's stock price today?

ENGN last traded at $1.74 as of Nov 20, 4:00 PM EST, down 1.14% on the day. Prices are delayed at least 15 minutes.

Who is enGene Therapeutics's CEO?

Mr. Ronald H. W. Cooper is the chief executive officer of enGene Therapeutics Inc., which has about 81 employees.

What is the ENGN 52-week high?

The 52-week high for ENGN is $12.25 and the 52-week low is $1.40. The stock is currently 85.8% below its high.

Compare ENGN